Broadcom Inc.
Long
Mis à jour

9/5/24 - $avgo - long print at $155

398
9/5/24 :: VROCKSTAR :: AVGO
long print at $155

- 7/10 idea. so for me that's small position
- 30x PE on name that's growing 20's: reasonable
- my fourth tier name after TSM > NVDA > ASML > AVGO
- i literally own NO semi's rn outside of some SOXL C's that are more managing exposure, book, length etc, and you'll never catch me writing about. i'm not a tik-sht-er. what you see is what you get. if you're old enough to get it... WYSIWYG culture here :)
- if you look at AVGO/SMH you'll see this is a "wanted" name. it's defn an AI play. it doesn't have such a cult following as NVDA. it's an outperformer tho.
- tough tape
- per my comment on GDLC becoming a 50% position today i'm making a risk-on bet into tmr's """job's report""". that being said...
- 2.5% fcf gen. great growth. good product. capable mgmt. not cheap. but you get what you pay for. and software is becoming more commoditized by the day. cursor is a-maz-ing. so we'll need to come back to the B2B names with a more critical eye in rest of '24 and 2025. but semi's can't be made in a terminal laboratory and the scale is just that. moat for now.
- so i like this one. i'm not necking out. but i'm long. might be calls ;)

lmk if you see it differently. i enjoy the comments!

V
Trade fermée manuellement
- future bright for AVGO, if you're a LT holder... think things are good
- price and valuation matter to me, if you've followed along
- for 2x the multiple vs. TSM, but for less growth and lower ebitda mgn and fcf generation... TSM is my horse.
- don't like shorting HQ companies hitting on all cylinders. semis tailwind will help
- but i think you can do better in TSM > NVDA > others for now.

just wanted to close the thread here... that i think the orange is mostly squeezed. only eyeing a much better oppty on a mkt sell off to re-enter this puppy.

always curious which semis you are fishing at, anon, the tailwind will be long.

V

Clause de non-responsabilité

Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.